Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...

Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year. That is according to French newspaper La Lettre, which said ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.